ClinicalTrials.gg
CompletedNCT05817812FREEDOMUpdated Jul 2, 2026

A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog Alfa

A Phase 3 interventional study of Efanesoctocog alfa in Hemophilia A, Severe, sponsored by Swedish Orphan Biovitrum. Completed at 30 sites in 14 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-07-02.

Sponsored by Swedish Orphan Biovitrum · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
93
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing efanesoctocog alfa in Hemophilia A — 1 open to participants now, 5 under way, 2 of them phase 3. efanesoctocog alfa · Hemophilia A.

Enrollment
4th of 11
93 · median 74
Started
2023
the only one that year
Phase 3
5 of 11
none open now
Registered
6th of 11
by date
Lead sponsor
5 of 11
Swedish Orphan Biovitrum

Among the 11 studies testing efanesoctocog alfa in Hemophilia A, this one is the 4th largest by enrollment, is the only one that started in 2023, is one of 5 in phase 3, and was the 6th registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

1 of the 11 studies testing efanesoctocog alfa in Hemophilia A is open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About efanesoctocog alfa

efanesoctocog alfa: first FDA approval 2023 (ALTUVIIIO), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing efanesoctocog alfa in Hemophilia A, or all of them as a file.
02

Study summary

FREEDOM is a multicentre, open-label, single-arm, phase 3b study in Europe that aims to enrol approximately 90 previously treated severe haemophilia A patients aged ≥12 years, currently on prophylaxis. After a run-in period of 30-45 days, patients will receive efanesoctocog alfa prophylaxis, 50 IU/kg once-weekly for 24 months (additional preventive dose not permitted). An activity tracker and an electronic patient diary will be used to collect data on physical activity, bleeds, factor dosing, pain, and injuries from screening throughout the study.

The primary objective is to describe changes in physical activities over 24 months on efanesoctocog alfa prophylaxis, with a primary endpoint of change from baseline in International Physical Activity Questionnaire (IPAQ) at month 24.

Secondary objectives include relationship between physical activity and other variables (bleeds, joint status, pain, injuries, and quality of life); changes in joint status as assessed by HEAD-US, HJHS and MRI; occurrence of bleeds, injuries, pain. Safety and tolerability of efanesoctocog alfa will also be evaluated.

03

Conditions studied

  • Hemophilia A, Severe

Keywords

  • Blood coagulation disorder
  • Coagulation protein disorder
  • Haemophilia
  • FVIII
  • Efanesoctocog alfa
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Previous treatment for haemophilia A with any marketed recombinant and/or plasma-derived FVIII for at least 150 EDs.
  • Having received prophylactic treatment with any marketed recombinant and/or plasma FVIII or emicizumab per local label for at least 12 months preceding enrolment.
  • Having 12 months documented pre-study treatment data regarding prophylactic treatment prescriptions and 6 months data on bleeding episodes prior to baseline visit.
  • Willingness and ability to complete training in the use of the study ePD and to use the ePD in their own smartphone throughout the study.
  • Willingness and ability to use the activity tracker provided by the sponsor to measure physical activity and heart rate.
  • Be able and willing to administer efanesoctocog alfa intravenously at home.

Key Exclusion Criteria:

  • Serious musculoskeletal and/or neurological impairment limiting the mobility and the physical ability to a degree that makes the patient unsuitable for the study as judged by the investigator.
  • Other known coagulation disorder(s) in addition to haemophilia A.
  • History and/or current positive inhibitor test defined as ≥0.6 BU/mL.
  • Treatment with NSAIDs above the maximum dose specified in the prescribing information within 2 weeks prior to screening.
  • Systematic treatment within 12 weeks prior to screening with chemotherapy and/or other drugs.
  • Treatment with an product within 30 days or 5.5 half-lives prior to screening, whichever is longer.
  • Major surgery within 12 weeks prior to screening or planned major orthopaedic surgery to occur during the study.
  • At baseline visit, patients who have not been compliant in using the activity tracker.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
93 participants (actual)

Study arms

  • Experimental
    Efanesoctocog alfa

    All patients will be treated intravenously once weekly with 50 IU/kg efanesoctocog alfa

    Drug: Efanesoctocog alfa

Interventions

  • Recombinant coagulation factor VIII Fc-von Willebrand Factor-XTEN fusion protein (rFVIIIFc-VWF-XTEN)

    Also known as: BIVV001

06

What researchers measure

Primary outcomes

  1. Change from baseline in International Physical Activity Questionnaire (IPAQ) scoring

    The IPAQ is a validated, 7-day recall questionnaire measuring current levels of physical activity. Scoring of the IPAQ results in a continuous variable in the form of total MET-minutes per week. Higher scores means higher physical activity level.

    Time frame: Baseline and month 24

Secondary outcomes

  1. Change from baseline in International Physical Activity Questionnaire (IPAQ) scoring

    The IPAQ is a validated, 7-day recall questionnaire measuring current levels of physical activity. Scoring of the IPAQ results in a continuous variable in the form of total MET-minutes per week. Higher scores means higher physical activity level.

    Time frame: Baseline and month 12

  2. International Physical Activity Questionnaire (IPAQ) score

    The IPAQ is a validated, 7-day recall questionnaire measuring current levels of physical activity. Scoring of the IPAQ results in a continuous variable in the form of total MET-minutes per week. Higher scores means higher physical activity level.

    Time frame: Baseline, month 6, 12, 18 and 24

  3. Change in mean daily minutes in physical activity

    Tracker-recorded

    Time frame: Run-in month, month 12 and 24

  4. Mean daily minutes of physical activity

    Tracker-recorded

    Time frame: Per 6-month period

  5. Change in type of workouts

    Patient and tracker reported

    Time frame: Run-in month, month 12 and 24

  6. Change in frequency of workouts

    Patient and tracker reported

    Time frame: Run-in month, month 12 and 24

  7. Change in duration of workouts

    Patient and tracker reported

    Time frame: Run-in month, month 12 and 24

  8. Change in patient reported intensity of workouts

    The patient will report workouts in a patient diary and rate the intensity on a 5 level scale. The levels are: 1 = easy, 2 = moderate, 3 = slightly challenging, 4 = exhausting, 5 = very exhausting. The changes will be calculated on a intra-patient basis

    Time frame: Run-in month, month 12 and 24

  9. Change in tracker recorded intensity of workouts

    The patient will be provided with an activity tracker that will automatically record workouts when the patient is wearing the tracker. The intensity levels will be based on the heart rate and will be presented on a 4 level scale. The levels are: 1 = out of range, 2 = fat burn, 3 = cardio, 4 = peak

    Time frame: Run-in month, month 12 and 24

  10. Mean value of patient and tracker reported type of workouts

    Type of workout will be transcribed into a risk level of participating in a given activity for a haemophilia patient. Risk levels are based on a rating of 1-3 where level 1 represents a low risk of causing a bleeding episode and level 3 represents a high risk. The mean value will be calculated per 6-month period

    Time frame: Per 6-month period

  11. Mean value of frequency of workouts

    Patient and tracker reported

    Time frame: Per 6-month period

  12. Mean value of duration of workouts

    Patient and tracker reported

    Time frame: Per 6-month period

  13. Mean value of patient reported intensity of workouts

    The patient will report workouts in a patient diary and rate the intensity on a 5 level scale. The levels are: 1 = easy, 2 = moderate, 3 = slightly challenging, 4 = exhausting, 5 = very exhausting. The mean value will be calculated per 6-month period

    Time frame: Per 6-month period

  14. Mean value of tracker recorded intensity of workouts

    The patient will be provided with an activity tracker that will automatically record workouts when the patient is wearing the tracker. The intensity levels will be based on the heart rate and will be presented on a 4 level scale. The levels are: 1 = out of range, 2 = fat burn, 3 = cardio, 4 = peak The mean value will be calculated per 6-month period

    Time frame: Per 6-month period

  15. Change in mean daily number of steps

    Tracker-recorded

    Time frame: Run-in month, month 12 and 24

  16. Mean daily number of steps

    Tracker-recorded

    Time frame: Per 6-month period

  17. Achieving WHO-recommended levels of MVPA

    Tracker-recorded

    Time frame: Run-in month, month 12 and 24

  18. Occurrence of bleeds in relation to workouts

    Time frame: Baseline to month 24

  19. Occurrence of pain in relation to workouts

    Time frame: Baseline to month 24

  20. Occurrence of injuries in relation to workouts

    Time frame: Baseline to month 24

  21. Occurrence of bleeding episodes impacting daily activity

    Time frame: Baseline to month 24

  22. Change from baseline in Haemophilia Joint Health Score (HJHS) score

    The six index joints (elbows, knees and ankles) will be examined and scored. The minimum score per joint is 0, the maximum score is 20. In addition, Gait is scored on a scale from 0 to 4 based on the number of skills that are not within the normal limits. The total score will be the sum of scores across all six joints plus the gait score (range from 0 to 124, with 0 being normal and 124 being the most severe disease).

    Time frame: Baseline, month 6, 12, 18, 24

  23. Change from baseline in Haemophilia Early Arthropathy Detection with Ultrasound (HEAD-US)

    The HEAD-US joint score will be calculated for six joints, the right and left ankle, knee, and elbow joints. The specific joint score is made up of three item scores, disease activity (synovitis), disease damage of articular surfaces, and disease damage of subchondral bone. Specific joint score is the sum of the three item scores for each specific joint. Its values range from 0 (minimum) to 8 (maximum).The total score represents the sum of item scores for abnormalities detected.

    Time frame: Baseline, month 12 and 24

  24. Change from baseline in haemophilic arthropathy assessed by the International Prophylaxis Study Group (IPSG) Magnetic Resonance Imaging (MRI) scale

    The IPSG scale is made up of two subscores, one for soft-tissue changes and one for osteochondral changes. MRI joint score is the sum of the soft tissue and osteochondral subscores for each joint, ranging from 0-17 where 0 is absence of damage. MRI total score is the sum of joint scores across all joints.

    Time frame: Baseline, month 24

  25. Target joint development (three or more spontaneous bleeds into a single joint within a consecutive 6-month period)

    The number and proportion of patients with target joint development and the total number of target joint developed will be assessed.

    Time frame: Month 6, 12, 18, 24

  26. Target joint resolution ( ≤2 bleeds into the joint within a consecutive 12-month period the joint is no longer considered a target joint)

    The number and proportion of patients with target joint resolution and the total number of target joint resolutions will be assessed

    Time frame: Month 6, 12, 18, 24

  27. Target joint recurrence (≥3 spontaneous bleeds in a single joint within any consecutive 6-month period after target joint resolution)

    The number and proportion of patients with target joint recurrence and the total number of target joint recurrence will be assessed

    Time frame: Month 6, 12, 18, 24

  28. Number of bleeding episodes

    Time frame: Per 6-month period and cumulative

  29. Annualized bleeding rate (ABR)

    Time frame: Baseline to month 24

  30. Total annualized efanesoctocog alfa consumption

    Time frame: Baseline to month 24

  31. Number of injections and dose to treat a bleeding episode

    Time frame: Baseline to month 24

  32. Pain reported via electronic patient diary

    The patient will report pain (cause of pain, location and intensity. The intensity will reported as mild, moderately low, moderately high, severe and worst possible.

    Time frame: Baseline to month 24

  33. Pain intensity reported in the Patient-Reported Outcomes Measurement Information System (PROMIS) Scale - Pain Intensity 3a

    The PROMIS Pain Intensity instrument assesses pain intensity on a 5-point Likert scale, ranging from 1 (had no pain) to 5 (very severe)

    Time frame: Baseline, month 6, 12, 18, 24

  34. Pain interference reported in the Patient-Reported Outcomes Measurement Information System (PROMIS) scale - Pain interference 6a

    The PROMIS Pain Interference 6a is a patient-assessed instrument and is to measure pain interference on a 5-point Likert scale, ranging from 1 (not at all) to 5 (very much)

    Time frame: Baseline, month 6, 12, 18, 24

  35. Quality of life assessed by EuroQoL 5-dimension 5-level (EQ-5D-5L)

    EQ-5D-5L assess 5 dimensions of health outcome (mobility, self-care, usual activities, pain/discomfort, anxiety/depression). Each of the dimensions in the EQ-5D-5L questionnaire is divided into 5 levels: * Level 1: indicating no problem * Level 2: indicating slight problems * Level 3: indicating moderate problems * Level 4: indicating severe problems * Level 5: indicating unable to/extreme problems Patients will select a level for each dimension that best describes their health status for that dimension. A 5 digit code will be obtained, made up of the response for each dimension. This code will then be converted to an index score.The EQ-5D-5L VAS is an overall assessment of health on a scale from 1-100 that the patient provides at the end of the EQ-5D-5L questionnaire. 100 represents the best health you can imagine and 0 represents the worst health you can imagine.

    Time frame: Baseline, month 6, 12, 18, 24

  36. Assessment of treatment preference

    This will be assessed with the Treatment Preference Survey that consists of 2 questions on perceived impact of treatment.

    Time frame: 24 months

  37. The occurrence of adverse events and serious adverse events

    Time frame: From screening to month 24

  38. The occurrence of clinically significant changes

    Assessed by physical examination, vital signs and laboratory tests

    Time frame: Baseline, month 6, 12, 18, 24

  39. Development of inhibitors (neutralizing antibodies directed against FVIII)

    Determined via the Nijmegen modified Bethesda assay

    Time frame: Baseline, month 6, 12, 18, 24

  40. The occurrence of thrombotic and embolic events

    Time frame: From screening to month 24

  41. Number of non-study medical care encounters

    The number and proportion of patients having non-study medical care encounter visits will be described, as well as the corresponding total number of visits.

    Time frame: From baseline to month 24

  42. Duration of non-study medical care encounters

    The duration of non-study medical care encounter visits will be described.

    Time frame: From baseline to month 24

07

Study locations

30 sites
  • Investigational Site
    Vienna, Austria
  • Investigational Site
    Zagreb, Croatia
  • Investigational Site
    Brno, Czechia
  • Investigational Site
    Prague, Czechia
  • Investigational Site
    Bordeaux, France
  • Investigational Site
    Le Kremlin-Bicêtre, France
  • Investigational Site
    Marseille, France
  • Investigational Site
    Strasbourg, France
  • Investigational Site
    Berlin, Germany
  • Investigational Site
    Frankfurt, Germany
  • Investigational Site
    Giessen, Germany
  • Investigational Site
    Hamburg, Germany
  • Investigational Site
    Athens, Greece
  • Investigational Site
    Dublin, Ireland
  • Investigational Site
    Catanzaro, Italy
  • Investigational Site
    Florence, Italy
  • Investigational Site
    Naples, Italy
  • Investigational Site
    Parma, Italy
  • Investigational Site
    Rome, Italy
  • Investigational Site
    Utrecht, Netherlands
  • Investigational Site
    Oslo, Norway
  • Investigational Site
    Ljubljana, Slovenia
  • Investigational Site
    Barcelona, Spain
  • Investigational Site
    Madrid, Spain
  • Investigational Site
    Oviedo, Spain
  • Investigational Site
    Lund, Sweden
  • Investigational Site
    Solna, Sweden
  • Investigational Site
    Canterbury, United Kingdom
  • Investigational Site
    Newcastle upon Tyne, United Kingdom
  • Investigational Site
    Oxford, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sobi's data sharing criteria and process for requesting access can be found at: https://www.sobi.com/en/policies

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Data sharing details ↗ · www.sobi.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2023 to primary completion in Jun 2026, 34 months.

Of 89 industry-sponsored phase 3 interventional studies under Hemophilia A, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 56. This study's 34 months is close to that.

Counting every sponsor, half of 91 studies reached it within 33 months; a quarter within 20 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2023
First posted
Apr 18, 2023
StartActual
Jul 31, 2023
Primary completionActual
Jun 2, 2026
CompletionActual
Jun 2, 2026
Last update
Jul 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05817812
Collaborators
Syneos Health
Responsible party
Sponsor
First posted
Apr 18, 2023
Start date
Jul 31, 2023
Primary completion
Jun 2, 2026
Completion
Jun 2, 2026
Last update
Jul 2, 2026

Study contacts

Study Physician, MD, PhD
study director · Swedish Orphan Biovitrum

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Efanesoctocog alfa

Start the discussion